EUCTR2008-005843-40-ES进行中（未招募）1 期
Estudio multicéntrico y abierto con Belinostat en pacientes con linfoma de células T periféricas (PTCL) reincidente o refractario.A Multicenter, Open-Label Trial of Belinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma - Belinostat PTC
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 129
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.A histologically confirmed diagnosis of PTCL based on pathology review at the local institution, using the most recent edition of the WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues as guidance leading to the diagnosis
- •2.Pathology material must be available at the site for each patient before enrolment so that it can be sent to the Sponsor (or designee) for central pathology review.
- •3.Patients must have relapsed or refractory disease after at least one prior systemic anticancer regimen. Systemic anticancer therapy is defined as chemotherapy or immunotherapy administered systemically.
- •4.Patients must have at least one site of disease measurable in two dimensions by computed tomography (CT).
- •5.Age ? 18 years.
- •6.Laboratory status as follows:
- •a.Absolute neutrophil count ? 1.0 x 109/L, platelets ? 50 x 109/L.
- •b.Total bilirubin ?1.5 x upper normal limit, or ? 3 x upper normal limit if documented hepatic involvement with lymphoma, or ? 5 x upper normal limit if history of Gilbert?s Disease.
- •c.Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 x upper normal limit (? 5 x upper normal limit if documented hepatic involvement with lymphoma).
- •d.Serum potassium within normal range.
- •e.Calculated creatinine clearance ? 45 mL/min/1.73 m2 based on Cockcroft and Gault?s method (Cockcroft 1976).
- •f.PT or INR, and APTT ? 1.5 x upper limit of normal unless patient is receiving anticoagulants. If patient is on anticoagulation therapy, levels should be within therapeutic range.
- •7.Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- •8.Estimated life expectancy greater than 3 months.
- •9.Negative pregnancy test for women of childbearing potential.
- •10.Signed informed consent form approved by the local Ethics Committee or Institutional Review Board.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Any use of anticancer therapies within 2 weeks prior to initiation of study treatment; in addition, patients should have recovered from prior treatment-related toxicities and meet laboratory and ECOG criteria for inclusion.
- •2.Any use of investigational therapies within 3 weeks prior to initiation of study treatment.
- •3.Major surgery within 2 weeks of study drug administration.
- •4.Relapse within 100 days of autologous or allogeneic bone marrow transplant.
- •5.Prior HDAC inhibitor therapy.
- •6.Patients with a diagnosis of:
- •?Precursor T-cell lymphoma or leukemia
- •?Adult T-cell lymphoma/leukemia (ATLL)
- •?T-cell prolymphocytic leukemia
- •?T-cell large granular lymphocytic leukemia
- •?Primary cutaneous type anaplastic large cell lymphoma
- •?Mycosis fungoides/Sezary syndrome
- •7.Co-existing active infection or any medical condition likely to interfere with trial procedures.
- •8.Significant cardiovascular disease (New York Heart Association Class III or IV cardiac disease), myocardial infarction within the past 6 months, unstable angina, unstable arrhythmia or a need for anti-arrhythmic therapy (use of frequency adjusting medication for atrial fibrillation is allowed, if stable medication for at least last month prior to randomization and medication not listed as causing Torsade de Points, see Section 16.2, Appendix B), or evidence of acute ischemia on ECG.
- •9.Baseline prolongation of QT/QTc interval, i.e., demonstration of a QTc interval > 450 msec; Long QT Syndrome; the required use of concomitant medication that may cause Torsade de Pointes (see Section 16.2 Appendix B for list of such medications).
- •10.Clinically significant central nervous system disorders with altered mental status or psychiatric disorders precluding understanding of the informed consent process and/or completion of the necessary studies.
- •11.Active concurrent malignancy (except adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix). If there is a history of prior malignancy, the patient must be disease free for greater than or equal to 2 years (except carcinoma in situ of breast, prostate cancer, or superficial bladder cancer).
- •12.Symptomatic or untreated central nervous system (CNS) metastases. Patients with previously treated CNS metastases which are asymptomatic at baseline are permitted.
- •13.Pregnant or breast-feeding women.
- •14.Women of childbearing age and potential who are not willing to use effective contraception during the study and until 30 days after last dose of study drug. Male patients or male patients who have female partners of childbearing age and potential who are not willing to use effective contraception during the study and until 30 days after last dose of study drug. Highly effective methods of birth control are defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence or vasectomised partner.
- •15.Known infection with HIV, hepatitis B or hepatitis C.
- •16.Patients that are not affiliated with social security (study centers in France only)
研究者
相似试验
进行中（未招募）
不适用
Estudio multicéntrico, abierto, de titulación, de 12 semanas de duración, con ampliación de tratamiento de mantenimiento de 9 meses, para demostrar la eficacia de SBR759 vs. Sevelamer HCI para disminuir los niveles séricos de fosfato en pacientes con enfermedad renal crónica en hemodiálisisEUCTR2006-001787-23-ESovartis Farmacéutica S.A378
进行中（未招募）
不适用
Estudio multicéntrico y abierto, de búsqueda de dosis para evaluar eficacia y seguridad de Givinostat administrado en dos dosis diferentes en pacientes que cursan artritis idiopática juvenil de evolución poliarticular (AIJ poli) que no están respondiendo adecuadamente al tratamiento estándar / A multicenter, open label, dose finding study to evaluate efficacy and safety of Givinostat administered in two different doses in patients with polyarticular course Juvenile Idiopathic Arthritis (poly JIA) not adequately responding to the standard treatmentArtritis Idiopática Juvenil de evolución poliarticular (AIJ poli) / Polyarticular course Juvenile Idiopathic Arthritis (poly JIA)MedDRA version: 12.1Level: LLTClassification code 10059176Term: Juvenile idiopathic arthritisEUCTR2010-019094-15-ESItalfarmaco S.p.A.20
进行中（未招募）
1 期
Estudio abierto, multicéntrico, randomizado, de fase III para investigar la eficacia y seguridad de bendamustina en comparación con bendamustina + RO5072759 (ga101) en pacientes con linfoma no hodgkin indolente, refractario a Rituximab An Open Label, Multicenter, randomized, phase III study to investigate the efficacy and safety of Bendamustine compared with Bendamustine + RO5072759 (GA101) in patients with Rituximab-refractory, indolent Non-Hodgkin?s LymphomaCD20+, indolent NHLMedDRA version: 12.1 Level: LLT Classification code 10029547 Term: Non-Hodgkin's lymphomaEUCTR2009-015504-25-ESGENENTECH, Inc396
进行中（未招募）
不适用
Estudio abierto, multicéntrico y aleatorizado sobre la eficacia y seguridad de la reducción de dosis de estavudina en pacientes en tratamiento antirretroviral que incluye estavudina a dosis estándar con buen control virológico e inmunológico. - REDOXAIDSEUCTR2004-001403-35-ESDoctor Pere Domingo284
进行中（未招募）
1 期
Estudio multicéntrico, prospectivo, abierto para evaluar la farmacocinética, tolerabilidad, seguridad y eficacia de la formulación pediátrica de bosentan, dos veces frente a tres veces al día en niños con hipertensión arterial pulmonar - FUTURE 3EUCTR2010-021825-11-ESActelion Pharmaceuticals Ltd.64